Imugene Limited announced the appointment of Dr. Steven Cha, MD, as Chief Medical Officer (CMO) and a member of the Company's executive management team. Prior to this he was Vice President, Oncology at Samumed, LLC, where he was responsible for building and establishing the oncology therapeutic indication and associated team, including the Clinical Development, Pre-Clinical, Toxicology, Clinical Operations, Medical Affairs, Clinical Pharmacology, and Translational Oncology Groups.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.051 AUD | -3.77% | -10.53% | -53.64% |
06-24 | Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6% | MT |
04-16 | Imugene Signs Deal to Sell Manufacturing Facility For $6 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.64% | 252M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team